Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer

Yuh Min Chen, Reury Perng Perng, Jacqueline Whang-Peng, Hsiao Wei Wu, Wei Chun Lin, Chun Ming Tsai

研究成果: 雜誌貢獻文章同行評審

3 引文 斯高帕斯(Scopus)


The aim of the present study was to determine the clinical activity and toxicity of a novel chemotherapy combination regimen of gemcitabine, ifosfamide and cisplatin (GIP), administered every 3 weeks, in patients with inoperable non-small cell lung cancer (NSCLC). From October 1998 to July 1999, 18 previously untreated stages IIIb (4) and IV (14) patients were enrolled into the study. Gemcitabine and ifosfamide (with mesna as uroprotection) was administered on days 1 and 6, at a dose of 1000 and 1500 mg/m2, respectively; and cisplatin was given on day 1 at a dose of 60 mg/m2, every 3 weeks. All 18 patients were evaluable for response and toxicity profiles. One patient achieved a complete response, and 11 patients achieved a partial response, with an overall response rate of 66.7% (95% CI, 45-89%). The main toxicity was hematological, a NCI grade 3-4 neutropenia in 16 patients (88.9%) during the treatment course. Febrile neutropenia occurred in three patients (16.6%). Grade 3 anemia occurred in eight patients (44.4%) and grade 3-4 thrombocytopenia occurred in 11 patients (61.1%). Non-hematological toxicity was mild and tolerable. No toxic death occurred. The median survival was 12.7 months and 1 year survival was 58.4%. The GIP combination chemotherapy produced a high response rate in advanced NSCLC; however, there was a relatively high percentage of hematological toxicity that still could be tolerated. A randomized trial comparing GIP to a two-drug combination of gemcitabine and cisplatin is planned.
頁(從 - 到)199-202
期刊Lung Cancer
出版狀態已發佈 - 12月 1 2000

ASJC Scopus subject areas

  • 腫瘤科
  • 肺和呼吸系統醫學
  • 癌症研究


深入研究「Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer」主題。共同形成了獨特的指紋。